CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

dehydroepiandrosterone

Small moleculeexperimental

Dehydroepiandrosterone (DHEA), also known as androstenolone, is an endogenous steroid hormone precursor. It is one of the most abundant circulating steroids in humans. DHEA is produced in the adrenal glands, the gonads, and the brain. It functions as a metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids both in the gonads and in various other tissues. However, DHEA also has a variety of potential biological effects in its own right, binding to an array of nuclear and cell surface receptors, and acting as a neurosteroid and modulator of neurotrophic factor receptors. — Wikipedia

Clinical trial activity

79 trials · 80 clinical orgs · 0 marketing orgs

Phase 1
14
Phase 2
36
Phase 3
27
Phase 4
7

Earliest trial started Aug 1, 1994 (NCT00004795)

Timeline

1990s

  1. Jan 1, 1994

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 1995

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dehydroepiandrosterone
  • dehydroepiandrosterone
  • dehydroepiandrosterone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07226362Phase 1Jun 9, 2025Aspeya Switzerland SA
NCT05935761Phase 2Apr 1, 2024Department of Veteran Affairs
NCT05900661Phase 2/Phase 3 (Phase 3)Jul 30, 2023Beni Suef University
NCT05263557N/AJun 30, 2022Royal College of Surgeons, Ireland, University of Birmingham, University of Oxford, William Beaumont Hospitals
NCT05562518Phase 4Mar 21, 2022Ghent University
NCT05316272N/AMar 11, 2022University of Colorado, Denver
NCT05471453N/AMar 2, 2022Kaohsiung Medical University
NCT05246865N/AOct 10, 2021University of Birmingham
NCT04493333Phase 2Dec 31, 2020AMAG Pharmaceuticals, Inc., University of Arkansas
NCT05586711Phase 4Dec 18, 2020Karolinska Institute
NCT04375657Phase 2Oct 31, 2020Intervene Immune, Inc.
NCT03783988Phase 1Jan 15, 2019Trophea Development AB, Uppsala University
NCT03648385Phase 2Nov 1, 2018Brown University, Rhode Island Hospital
NCT03491007Phase 2Oct 1, 2018Department of Veteran Affairs
NCT03227458N/AJan 31, 2018University of Colorado, Denver
NCT03383133Early Phase 1 (Phase 1)Jan 31, 2018Yeshiva University
NCT03418363Phase 2Jan 16, 2018Oregon Health and Science University
NCT03228732Early Phase 1 (Phase 1)Dec 19, 2017University of Maryland
NCT04066478Phase 2/Phase 3 (Phase 3)Oct 8, 2017Imperial College London
NCT03438812N/ASep 6, 2017Kaohsiung Medical University, University of Messina
Showing 20 of 79 trials
Page 1 / 4

Organizations

Research & Development (80)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Center for Research Resources (NCRR)Government5431994
Cairo UniversityAcademic/Hospital4422014
Eastern Virginia Medical SchoolAcademic/Hospital4012007
EndoCeutics Inc.For profit4412007
National Institute on Aging (NIA)Government4322000
Washington University in St. LouisAcademic/Hospital4232001
Laval UniversityAcademic/Hospital3322004
National Institutes of Health (NIH)Government3022002
Northwestern UniversityAcademic/Hospital3021994
University of BordeauxAcademic/Hospital3322002
University of Colorado, DenverAcademic/Hospital3212000
Department of Veteran AffairsGovernment2212018
Fudan UniversityAcademic/Hospital2212014
GrunenthalFor profit2212014
Kaohsiung Medical UniversityAcademic/Hospital2212017
Mayo ClinicAcademic/Hospital2212003
National Cancer Institute (NCI)Government2012007
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government2022001
Oregon Health and Science UniversityAcademic/Hospital2222007
Tel Aviv UniversityAcademic/Hospital2212005
80 organizations
Page 1 / 4